Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase III Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)

NCT04793932 is registered in ClinicalTrials.gov with Associazione Italiana per lo Studio del Pancreas as lead sponsor.

NCT NCT04793932
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04793932 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase III Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC)
Lead sponsor
Associazione Italiana per lo Studio del Pancreas
Phase
Phase 3
Overall status
Active, not recruiting
Start date
November 3, 2020
Completion date
January 31, 2026
Enrollment
261 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

pancreas ductal adenocarcinoma